Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $583.34 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $248.65 | 2 | $0 (2021) |
| ViiV Healthcare Company | $125.44 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $109.37 | 1 | $0 (2023) |
| Ferring Pharmaceuticals Inc. | $53.71 | 1 | $0 (2023) |
| PFIZER INC. | $31.66 | 2 | $0 (2021) |
| Lilly USA, LLC | $14.51 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $288.52 | 3 | ViiV Healthcare Company ($125.44) |
| 2022 | $14.51 | 1 | Lilly USA, LLC ($14.51) |
| 2021 | $280.31 | 4 | AstraZeneca Pharmaceuticals LP ($248.65) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $53.71 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/12/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $109.37 | General |
| 09/08/2023 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $125.44 | General |
| 04/20/2022 | Lilly USA, LLC | TRULICITY (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Diabetes | ||||||
| 11/15/2021 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/13/2021 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/23/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $124.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/16/2021 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $123.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
About Dr. Curran Perry, MD
Dr. Curran Perry, MD is a Infectious Disease healthcare provider based in Williamsport, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2019. The National Provider Identifier (NPI) number assigned to this provider is 1386105393.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Curran Perry, MD has received a total of $583.34 in payments from pharmaceutical and medical device companies, with $288.52 received in 2023. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($583.34).
Practice Information
- Specialty Infectious Disease
- Location Williamsport, PA
- Active Since 03/31/2019
- Last Updated 04/21/2025
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1386105393
Products in Payments
- FARXIGA (Drug) $124.70
- LOKELMA (Drug) $123.95
- REBYOTA (Biological) $53.71
- ELIQUIS (Drug) $31.66
- TRULICITY (Drug) $14.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.